Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
What sector does Evelo Biosciences Inc (EVLO) operate in?
Evelo Biosciences Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Evelo Biosciences Inc (EVLO) current stock price?
As of the latest data, Evelo Biosciences Inc stock price is $0.00, with a previous close of $0.00.
What is Evelo Biosciences Inc (EVLO) current market capitalization?
Evelo Biosciences Inc market cap is approximately 1.90 thousand.
What is Evelo Biosciences Inc (EVLO) Earnings Per Share (EPS)?
The trailing EPS is -$3.91.
Does Evelo Biosciences Inc (EVLO) pay dividends?
No. Evelo Biosciences Inc does not pay a dividend.
What is Evelo Biosciences Inc (EVLO) beta (volatility) score?
Evelo Biosciences Inc has a beta of -25.237, indicating lower volatility than the overall market.
